The Vanderbilt Transplant Center performed a record number of solid organ transplants in fiscal year 2021 (FY 21) — 637 life-saving procedures among its adult and pediatric programs — despite occurring entirely during the COVID-19 pandemic.
Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases. These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death.
Reporters are invited to join a live Q&A discussion of exciting research announcements at the forefront of the life sciences during a virtual press conference for the Experimental Biology (EB) 2021 meeting. The press conference will be held online from 1–1:45 p.m. EDT on Monday, April 26, 2021 (RSVP by Friday, April 23).
Historic case launches Mount Sinai’s Tracheal Transplant Program for treating patients worldwide, including those with severe intubation damage after COVID-19
Patients with high levels of antibodies face major challenges getting a transplant. These highly sensitized patients have a higher risk of death while waiting for suitable organs. But there is new hope for highly sensitized patients in need of a combined heart and liver transplant, thanks to an innovative surgical approach at Mayo Clinic.
‘Tissue-resident memory T cells’, whose main function is to provide local protection against re-infection, contribute to chronic transplant rejection.
Vanderbilt University Medical Center performed more heart transplants in 2020 than any other center in the world — 124 adult hearts, 23 pediatric hearts and VUMC’s first heart-lung transplant since 2006.
UC San Diego Health’s lung, heart, kidney and liver transplant programs rank at the top nationally in the latest biannual Scientific Registry of Transplant Recipients (SRTR) report. Innovative treatment and multi-disciplinary care contribute to the high rankings for one-year survival outcomes.
In a year rocked by the COVID-19 (coronavirus) pandemic, the Cedars-Sinai Comprehensive Transplant Center is on track to match or break records.
A multi-institutional study finds that COVID-19 can be found in post-mortem corneal tissue, highlighting the importance of the donor screening process.
Researchers at the University of Pittsburgh School of Medicine have combined synthetic biology with a machine learning algorithm to create human liver organoids with blood and bile handling systems. When implanted into mice with failing livers, the lab-grown replacement livers extended life.
A new national policy was created to make determining who receives a heart transplant more fair. But new data shows it changed some practice patterns, too.
The Mayo Clinic heart transplant program in Arizona has been recognized as one of the top transplant programs in the U.S. based on quality and patient outcomes. The Scientific Registry of Transplant Recipients, a national medical database that evaluates solid organ transplantation in the U.S., has reported that the Mayo program has achieved the top long-term outcomes in the country.
A new study analyzes death risk from COVID-19 in organ transplant recipients and finds one treatment method greatly increased the risk.
Surgeons at UI Health — the University of Illinois Chicago’s clinical and academic health enterprise — have performed the world’s first robotic-assisted double-kidney removal followed immediately by a living-donor kidney transplant in a patient with severe polycystic kidney disease.
Patients with large polycystic kidneys in need of a kidney transplant can have their diseased kidneys safely removed laparoscopically at the same time as their transplant surgery. That is the finding of a Mayo Clinic study recently published in the American Journal of Transplantation.
UC San Diego Health is the first hospital on the West Coast to perform heart transplant surgery from a donor after circulatory death using a new portable organ care system. The investigational procedure could significantly decrease transplant waiting list times and improve patient outcomes.
Researchers at the Georgia Institute of Technology and University of Missouri developed a new microgel drug delivery method that could extend the effectiveness of pancreatic islet transplantations — from several years to possibly the entire lifespan of a recipient.
A pandemic story with a happy ending. How a baby received a new heart after months of waiting amid the pandemic.
Two physicians — David Serur, M.D., and Vikram Wadhera, M.B. B.S. — have joined the surgical team at Hackensack Meridian Hackensack University Medical Center’s Division of Organ Transplantation.
A multidisciplinary team from Columbia Engineering and Vanderbilt University has now demonstrated that severely injured donor lungs that have been declined for transplant can be recovered outside the body by a system that uses cross-circulation of whole blood between the donor lung and an animal host. For the first time, a severely injured human lung that failed to recover using the standard clinical EVLP was successfully recovered during 24 hours on the team’s cross-circulation platform.
Researchers at The Ohio State University College of Medicine are the first to identify an immune cell that may predict a transplant patient’s risk of developing antibodies that can cause organ rejection. This discovery could lead to the development of therapies to prevent complications after transplant surgery.
Using skin cells from human volunteers, researchers at the University of Pittsburgh School of Medicine have created fully functional mini livers, which they then transplanted into rats. In this proof-of-concept experiment, the lab-made organs survived for four days inside their animal hosts.
Inspired by a tactic cancer cells use to evade the immune system, University of Pittsburgh researchers have engineered tiny particles that can trick the body into accepting transplanted tissue as its own, while leaving the immune system intact.
Mesenchymal stromal cells from fat tissue and bone marrow are widely used in therapeutic trials for their anti-inflammatory qualities, but new Mayo Clinic research finds that liver cells may be of greater value.
The study, published in Liver Transplantation, finds that liver mesenchymal stromal cells have immunoregulatory qualities that make them more effective than similar cells derived from adipose, or fat, tissue and bone marrow.
Vanderbilt University Medical Center is launching a living liver donor transplant program, significantly increasing the number of available organs for life-saving transplants